CCN2 and idiopathic pulmonary fibrosis: Finally, we further validated our results in PCLS from end-stage IPF tissue explants and found that treatment with VP reduced LOX expression as well as CTGF, WISP1 and FN1 in IPF tissue (Fig. 7E, F).